Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children, affecting thousands of young patients ...
Rheumatoid arthritis (RA) may cause inflammation in your eyes, leading to complications such as dry eyes, redness, and floaters, among others. Early treatment may prevent these conditions from ...
YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...
The FDA approved expanded indications of Yuflyma and its unbranded version to treat hidradenitis suppurativa in adolescents aged 12 years and older and uveitis in children aged 2 years and older, ...
GLP-1 RA prescriptions were associated with greater protection against uveitis compared with the cohorts taking metformin and insulin. (HealthDay News) — Glucagon-like peptide 1 receptor agonists (GLP ...
Southwood TR, Woo P . Classification and nomenclature in juvenile arthritis. In: Silman and Symmons classification and assessment of rheumatic diseases. London: Bailliere Tindall, 1995;9:331–5.
US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty: Incheon, South Korea Monday, October 20, 2025, 17:00 Hrs [IST] Celltrion, ...
Uveitis is a condition that occurs in the uvea, or the middle area of the eye. Because the uvea contains the blood vessels that supply nutrients to the eye, any form of uveitis may be serious and may ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback